A Longitudinal Observational Follow-up of the PRECEPT Study Cohort

NCT ID: NCT00605163

Last Updated: 2008-03-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

530 participants

Study Classification

OBSERVATIONAL

Study Start Date

2006-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to longitudinally follow consenting clinical trial participants who participated in PRECEPT (A Randomized, Double Blind, Placebo Controlled, Dose Finding Study to Assess the Efficacy and Safety of CEP 1347 in Patients With Early Parkinson's Disease). The study will assess the clinical and imaging outcomes relevant to the natural history of Parkinson's disease (PD), as well as determine early biomarkers of the disease.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson Disease

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Parkinson disease, observational, longitudinal

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participation in the PRECEPT study
* Willing and able to give informed consent

Exclusion Criteria

* Patients will be excluded from participating in the the study if either of the criteria stated above is not met
Minimum Eligible Age

30 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

Sponsor Role collaborator

H. Lundbeck A/S

INDUSTRY

Sponsor Role collaborator

Parkinson's Disease Foundation

OTHER

Sponsor Role collaborator

United States Department of Defense

FED

Sponsor Role collaborator

The Parkinson Study Group

NETWORK

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

University of Rochester Clinical Trials Coordination Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Barrow Neurological Institute

Phoenix, Arizona, United States

Site Status

Sun Health Research Institute

Sun City, Arizona, United States

Site Status

University of Arkansas for Medical Sciences

Little Rock, Arkansas, United States

Site Status

The Parkinson's & Movement Disorder Institute

Fountain Valley, California, United States

Site Status

University of California Irvine

Irvine, California, United States

Site Status

University of San Diego

La Jolla, California, United States

Site Status

University of Southern California

Los Angeles, California, United States

Site Status

Pacific Neuroscience Medical Group

Oxnard, California, United States

Site Status

University of California Davis

Sacramento, California, United States

Site Status

The Parkinson's Institute

Sunnyvale, California, United States

Site Status

University of Colorado Health Sciences Center

Aurora, Colorado, United States

Site Status

Colorado Neurological Institute

Littleton, Colorado, United States

Site Status

Institute for Neurogenerative Disorders

New Haven, Connecticut, United States

Site Status

Mayo Clinic Jacksonville

Jacksonville, Florida, United States

Site Status

University of South Florida

Tampa, Florida, United States

Site Status

Cleveland Clinic Florida-Weston

Weston, Florida, United States

Site Status

Medical College of Georgia

Augusta, Georgia, United States

Site Status

Northwestern University

Chicago, Illinois, United States

Site Status

Rush University Medical Center

Chicago, Illinois, United States

Site Status

University of Chicago

Chicago, Illinois, United States

Site Status

University of Iowa

Iowa City, Iowa, United States

Site Status

University of Kansas Medical Center

Kansas City, Kansas, United States

Site Status

LSU Health Science Center Shreveport

Shreveport, Louisiana, United States

Site Status

Johns Hopkins University

Baltimore, Maryland, United States

Site Status

University of Maryland School of Medicine

Baltimore, Maryland, United States

Site Status

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States

Site Status

Boston University

Boston, Massachusetts, United States

Site Status

Brigham & Women's Hospital

Boston, Massachusetts, United States

Site Status

Massachusetts General Hospital

Boston, Massachusetts, United States

Site Status

University of Minnesota

Minneapolis, Minnesota, United States

Site Status

Creighton University

Omaha, Nebraska, United States

Site Status

UMDNJ Robert Wood Johnson Medical School

New Brunswick, New Jersey, United States

Site Status

Albany Medical College

Albany, New York, United States

Site Status

North Shore-LIJ Health System

Manhasset, New York, United States

Site Status

Beth Israel Medical Center

New York, New York, United States

Site Status

Columbia University

New York, New York, United States

Site Status

University of Rochester

Rochester, New York, United States

Site Status

Duke University Medical Center

Durham, North Carolina, United States

Site Status

University of Cincinnati/Cincinnati Children's Hospital

Cincinnati, Ohio, United States

Site Status

Oregon Health & Science University

Portland, Ohio, United States

Site Status

Medical University of Ohio

Toledo, Ohio, United States

Site Status

Milton S. Hershey Medical Center

Hershey, Pennsylvania, United States

Site Status

University of Pennsylvania

Philadelphia, Pennsylvania, United States

Site Status

NeuroHealth Parkinson's Disease Movement Disorders Center

Warwick, Rhode Island, United States

Site Status

University of Tennessee-Memphis

Memphis, Tennessee, United States

Site Status

Baylor College of Medicine

Houston, Texas, United States

Site Status

University of Virginia

Charlottesville, Virginia, United States

Site Status

University of Calgary

Calgary, Alberta, Canada

Site Status

University of Alberta

Edmonton, Alberta, Canada

Site Status

London Health Sciences Centre

London, Ontario, Canada

Site Status

Ottawa Hospital Civic Site

Ottawa, Ontario, Canada

Site Status

Toronto Western Hospital, University Health Network

Toronto, Ontario, Canada

Site Status

University of Sherbrooke

Fleurimont, Quebec, Canada

Site Status

Hotel-Dieu Hospital-CHUM

Montreal, Quebec, Canada

Site Status

Saskatoon Disrict Health Board Royal University Hospital

Saskatoon, Saskatchewan, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Canada

References

Explore related publications, articles, or registry entries linked to this study.

Parkinson Study Group PRECEPT Investigators. Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Neurology. 2007 Oct 9;69(15):1480-90. doi: 10.1212/01.wnl.0000277648.63931.c0. Epub 2007 Sep 19.

Reference Type BACKGROUND
PMID: 17881719 (View on PubMed)

Latourelle JC, Beste MT, Hadzi TC, Miller RE, Oppenheim JN, Valko MP, Wuest DM, Church BW, Khalil IG, Hayete B, Venuto CS. Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson's disease: a longitudinal cohort study and validation. Lancet Neurol. 2017 Nov;16(11):908-916. doi: 10.1016/S1474-4422(17)30328-9. Epub 2017 Sep 25.

Reference Type DERIVED
PMID: 28958801 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

http://www.Parkinson-Study-Group.org

The Parkinson Study Group (PSG) is a non-profit, cooperative group of Parkinson's disease experts from medical centers in theUnited States and Canada who are dedicated to improving treatment for persons affected by Parkinson's disease.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NINDS 5 U01NS050095-02

Identifier Type: -

Identifier Source: secondary_id

U01NS050095

Identifier Type: NIH

Identifier Source: secondary_id

View Link

U01NS050095_PostCEPT

Identifier Type: -

Identifier Source: org_study_id